Ir al contenido

Quasi-Experimental Evidence on Medicine Access and Effective Coverage in a Fragmented Health System

Health system fragmentation creates institutional barriers that impede effective coverage and equitable medicine distribution. Evaluating these structural bottlenecks through quasi-experimental evidence clarifies how misaligned financing and uncoordinated supply chains undermine universal health goals. Addressing systemic divides requires integrated purchasing mechanisms, standardized supply-chain governance, and sustainable pharmaceutical financing.

Objetivo

Examine how institutional fragmentation affects equitable medicine access and effective coverage outcomes across low- and middle-income health systems.

Metodología

Comparative secondary evidence synthesis across multi-country health system indicators, procurement policies, and stratified utilization datasets.

Novedad científica

Demonstrates the systematic gap between nominal health insurance entitlement and verified pharmaceutical availability under fragmented financing.

Vista previa del documento

Esta es una vista previa breve. La versión completa incluye texto ampliado para todas las secciones, una conclusión y una bibliografía formateada.

Master's Thesis

Degree:
Quasi-Experimental Evidence on Medicine Access and Effective Coverage in a Fragmented Health System

Author:

Group

First M. Last

Advisor:

Dr. First Last

City, 2026

Contents

Carátula
Declaración de Uso de IA
Abstract
Introduction
2. Estado del Arte: Universal Coverage and Medicine Supply Disparities
2.1. Fragmentation in Financing Mechanisms and Risk Pooling
2.2. Determinants of Essential Pharmaceutical Availability
3. Marco Teórico: Systems Architecture and Effective Health Coverage
3.1. Governance Frameworks for Rational Drug Utilization
3.2. Structural Inequities in Public-Private Service Delivery
4. Methodology: Quasi-Experimental and Comparative Evaluation Designs
4.1. Identification Strategies and Secondary Evidence Synthesis
4.2. Metric Standardization across Disaggregated Subsystems
5. Resultados: Access Gaps and Financial Protection Trajectories
6. Discusión: Structural Bottlenecks and Policy Implications
Conclusion
Bibliography

Introduction

Health system fragmentation poses a structural barrier to achieving universal health coverage, as segmented financing pools and uncoordinated delivery channels systematically disrupt access to essential pharmaceuticals [1]. While nominal population enrollment often expands rapidly under decentralized reform agendas, effective coverage remains compromised by severe supply disruptions, drug stock-outs, and non-uniform clinical availability across socioeconomic tiers [2]. Evaluating these multi-tiered disparities requires robust quasi-experimental and comparative evidence to untangle statutory entitlements from actual point-of-care delivery.

Institutional misalignment between central procurement bodies and decentralized provider networks frequently drives persistent out-of-pocket medical expenditure, disproportionately penalizing vulnerable and rural households [3]. Even where comprehensive benefit packages exist, fragmented administrative rules and mixed public-private provider incentives undermine equitable therapeutic distribution [1]. Consequently, nominal financial protection fails to prevent catastrophic medical spending when pharmaceutical supply chains break down, illustrating the profound divergence between nominal coverage metrics and verified therapeutic access [2].

This paper examines the mechanisms governing medicine access and effective coverage within structurally fragmented health systems through a systematic synthesis of comparative policy frameworks and health service indicators. By evaluating evidence across tiered public and private sectors, the study identifies governance bottlenecks, assesses supply-chain vulnerabilities, and articulates institutional strategies necessary to align pharmaceutical financing with equitable, high-quality care outcomes [3].

6. Discusión: Structural Bottlenecks and Policy Implications

The empirical findings demonstrate that expanding formal insurance coverage fails to secure effective pharmaceutical access when health systems remain institutionally fragmented. Scholarly consensus emphasizes that nominal enrollment does not automatically translate into consistent service delivery or financial protection, particularly in middle-income settings where segmented risk pools restrict cross-subsidization and dilute collective bargaining power (Translating Coverage into Access, 2026). Without robust strategic purchasing and regulatory enforcement across mixed delivery systems, structural bottlenecks sustain service disruptions and household financial exposure (Translating Coverage into Access, 2026). Concurrently, national reform analyses confirm that sustainable medicine financing and equitable access depend on coordinated governance across pricing frameworks, rational drug selection, and resilient supply-chain infrastructure (How and Why Pharmaceutical Reforms Contribute to Universal Health Coverage, 2023). However, a critical research gap persists regarding how specific institutional mechanisms mitigate disparities across disaggregated subsystems. Existing scholarship largely assesses aggregate macro-level trends or isolated programmatic reforms, overlooking the empirical interactions between decentralized purchasing arrangements and localized medicine availability. This gap impedes the formulation of unified procurement strategies across segmented payer networks. Furthermore, notable limitations constrain the present synthesis, as secondary administrative datasets frequently exhibit reporting gaps, inconsistent recording of public financing flows, and scarce longitudinal metrics tracking pharmaceutical distribution (How and Why Pharmaceutical Reforms Contribute to Universal Health Coverage, 2023). Addressing these structural barriers requires institutional harmonization and standardized monitoring frameworks to guarantee equitable medicine delivery across fragmented health systems.

References

  1. How and why pharmaceutical reforms contribute to universal health coverage through improving equitable access to medicines: a case of Ghana
    Augustina Koduah
    Enlace DOI
  2. Does Universal Health Coverage Improve Access to Healthcare? Insights from Rwanda’s National Health System
    Musinga Abdulswamad
    Enlace DOI
  3. Translating Coverage into Access: Evidence-Based Analysis of Universal Health Coverage Across Low-and Middle-Income Countries Post-COVID
    Swalin Suraj Pradhan
    Enlace DOI
  4. Digital navigation as an access barrier: waiting times, equity, and universal health coverage in a digitalizing health system
    Eva Memmel, Lukas Kerschbaumer
  5. Universal Health Coverage
    K. Srinath Reddy, Manu Raj Mathur
  6. TOWARDS UNIVERSAL HEALTH COVERAGE: ACCESS AND UTILIZATION OF HEALTH CARE SERVICES IN BHUTAN
    Tshering Wangdi
  7. Making Universal Health Coverage Effective in Low- and Middle-Income Countries: A Blueprint for Health Sector Reforms
    Peter O. Otieno, Gershim Asiki
  8. Could universal health care coverage restrict access? The mixed effects of universal coverage on minorities' receipt of obstetric care in northern Thailand
    Stephanie M Koning

Bibliografía

Fuentes VerificadasNormas de FormatoAlta OriginalidadModelos Pro
🔥 25% OFF

Investigación

APA 7ª Edición (con adaptación "y otros")

US$ 14US$ 18
  • 30+ páginas
  • Alta originalidad
  • Exportar a Word
  • Formato correcto
  • Vista previa pública
    La vista previa de otro autor no puede hacerse privada. Tu trabajo será privado y completamente único.
  • Bibliografía (50+, APA 7ª Edición)
    +US$ 1
  • Añadir fuentes alternativas (Noticias, .gov, .edu)

Investigación

APA 7ª Edición (con adaptación "y otros")